37 results
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
2 May 24
Regeneron Reports First Quarter 2024 Financial and Operating Results
7:06am
positioned to continue our leadership in retinal diseases. Dupixent continues to grow at a remarkable pace seven years into its launch and is currently
8-K
EX-99.1
REGN
Regeneron Pharmaceuticals, Inc.
8 Jan 24
2 Strategy & Business Update J.P.Morgan Healthcare Conference 2024 Co - Founder, Board Co - Chair, President & Chief Executive Officer
6:30am
franchise for prolonged leadership Exceptional Dupixent clinical and commercial execution ; unprecedented data in eosinophilic COPD to enable potential … for global leadership in oncology Potential for up to three FDA - approved products by end of 2024, spanning solid and hematological malignancies Libtayo
SC TO-T
EX-99
DBTX
Decibel Therapeutics, Inc.
25 Aug 23
Third party tender offer statement
7:46am
and leadership of all U.S. commercial functions, including medical affairs, business development, finance, human resources, legal, operations … , and a member of the board of directors of NPS Pharmaceuticals, Inc. Before joining NPS, he served in various leadership positions in the biopharmaceutical
8-K
4ov0ab 5nogb41rkfcg
14 Jun 23
Amendments to Articles of Incorporation or Bylaws
4:07pm
DEFA14A
vxfvh0c9i389a60sq
17 May 23
Additional proxy soliciting materials
4:04pm
CORRESP
06fom 0donf
7 Oct 22
Correspondence with SEC
12:00am
UPLOAD
6e730bqoj5f83m5y3th
21 Sep 22
Letter from SEC
12:00am
SC TO-T
EX-99
tknc nx7pubbt9s92
2 May 22
Third party tender offer statement
7:48am
DEFA14A
pq2 8jndz
21 Apr 22
Additional proxy soliciting materials
4:21pm
8-K
EX-99.1
3i85z4e sb4
10 Jan 22
Results of Operations and Financial Condition
6:02am
DEFA14A
2t94 jsu7pzbl
23 Apr 21
Additional proxy soliciting materials
4:21pm
8-K
EX-99.1
25ggosqhr
11 Jan 21
Results of Operations and Financial Condition
6:03am
8-K
evuopw 4rurfl
5 Jan 21
Departure of Directors or Certain Officers
6:03am